Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.73 Million USD | 59.93% |
| 2022 | -6.54 Million USD | 25.87% |
| 2021 | -8.63 Million USD | -107.62% |
| 2020 | -6.01 Million USD | 27.31% |
| 2019 | -6.11 Million USD | 63.66% |
| 2018 | -13.52 Million USD | -5.48% |
| 2017 | -14.92 Million USD | -28.9% |
| 2016 | -12.23 Million USD | 7.7% |
| 2015 | -12.55 Million USD | -61.95% |
| 2014 | -7.74 Million USD | -159.79% |
| 2013 | -2.98 Million USD | 28.94% |
| 2012 | -4.63 Million USD | 26.65% |
| 2011 | -5.72 Million USD | -71.93% |
| 2010 | -3.32 Million USD | -135.7% |
| 2009 | -1.41 Million USD | -176.78% |
| 2008 | -510.19 Thousand USD | -999.29% |
| 2007 | -46.41 Thousand USD | -36.01% |
| 2006 | -34.12 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -223 Thousand USD | -33.33% |
| 2023 Q2 | -253 Thousand USD | 80.83% |
| 2023 Q1 | -1.32 Million USD | 12.41% |
| 2023 Q3 | -586 Thousand USD | -131.62% |
| 2023 Q4 | -579 Thousand USD | 1.19% |
| 2023 FY | - USD | 59.93% |
| 2022 Q1 | -1.92 Million USD | 20.79% |
| 2022 FY | - USD | 25.87% |
| 2022 Q4 | -1.5 Million USD | -10.56% |
| 2022 Q3 | -1.36 Million USD | 21.94% |
| 2022 Q2 | -1.74 Million USD | 9.44% |
| 2021 Q2 | -3.34 Million USD | -223.19% |
| 2021 Q3 | -1.82 Million USD | 45.5% |
| 2021 Q4 | -2.43 Million USD | -33.52% |
| 2021 FY | - USD | -107.62% |
| 2021 Q1 | -1.03 Million USD | 22.24% |
| 2020 FY | - USD | 27.31% |
| 2020 Q2 | -1.25 Million USD | -67.69% |
| 2020 Q1 | -746 Thousand USD | 45.15% |
| 2020 Q3 | -832 Thousand USD | 33.49% |
| 2020 Q4 | -1.33 Million USD | -59.98% |
| 2019 Q1 | -1.9 Million USD | 59.6% |
| 2019 Q3 | -986 Thousand USD | 47.05% |
| 2019 Q4 | -1.36 Million USD | -37.93% |
| 2019 FY | - USD | 63.66% |
| 2019 Q2 | -1.86 Million USD | 2.26% |
| 2018 Q2 | -4.36 Million USD | 0.34% |
| 2018 Q4 | -4.71 Million USD | -105.81% |
| 2018 FY | - USD | -5.48% |
| 2018 Q1 | -4.37 Million USD | 14.04% |
| 2018 Q3 | -2.29 Million USD | 47.49% |
| 2017 Q3 | -3.74 Million USD | -16.94% |
| 2017 FY | - USD | -28.9% |
| 2017 Q4 | -5.09 Million USD | -35.85% |
| 2017 Q2 | -3.2 Million USD | -11.28% |
| 2017 Q1 | -2.88 Million USD | -17.74% |
| 2016 Q2 | -3.16 Million USD | -30.42% |
| 2016 Q3 | -3.54 Million USD | -12.07% |
| 2016 Q1 | -2.42 Million USD | 17.79% |
| 2016 FY | - USD | 7.7% |
| 2016 Q4 | -2.44 Million USD | 30.99% |
| 2015 Q1 | -4.25 Million USD | -33.0% |
| 2015 Q3 | -2.74 Million USD | -5.46% |
| 2015 Q2 | -2.6 Million USD | 38.88% |
| 2015 FY | - USD | -61.95% |
| 2015 Q4 | -2.95 Million USD | -7.62% |
| 2014 Q4 | -3.19 Million USD | -46.27% |
| 2014 FY | - USD | -159.79% |
| 2014 Q3 | -2.18 Million USD | -49.13% |
| 2014 Q2 | -1.46 Million USD | -63.62% |
| 2014 Q1 | -896.2 Thousand USD | 17.37% |
| 2013 FY | - USD | 28.94% |
| 2013 Q1 | -408.91 Thousand USD | 72.99% |
| 2013 Q2 | -688.74 Thousand USD | -68.43% |
| 2013 Q3 | -800.75 Thousand USD | -16.26% |
| 2013 Q4 | -1.08 Million USD | -35.44% |
| 2012 Q4 | -1.51 Million USD | -111.42% |
| 2012 FY | - USD | 26.65% |
| 2012 Q2 | -1.07 Million USD | -19.97% |
| 2012 Q1 | -894.15 Thousand USD | 26.08% |
| 2012 Q3 | -716.15 Thousand USD | 33.24% |
| 2011 FY | - USD | -71.93% |
| 2011 Q3 | -2.22 Million USD | -72.53% |
| 2011 Q4 | -1.2 Million USD | 45.72% |
| 2011 Q1 | -992.62 Thousand USD | -18.49% |
| 2011 Q2 | -1.29 Million USD | -30.12% |
| 2010 FY | - USD | -135.7% |
| 2010 Q2 | -1.18 Million USD | -123.3% |
| 2010 Q4 | -837.73 Thousand USD | -7.19% |
| 2010 Q3 | -781.52 Thousand USD | 33.79% |
| 2010 Q1 | -528.6 Thousand USD | -82.61% |
| 2009 FY | - USD | -176.78% |
| 2009 Q4 | -289.46 Thousand USD | 54.9% |
| 2009 Q3 | -641.87 Thousand USD | -103.08% |
| 2009 Q2 | -316.06 Thousand USD | -71.66% |
| 2009 Q1 | -184.12 Thousand USD | 14.9% |
| 2008 Q1 | -15.19 Thousand USD | 6.23% |
| 2008 Q2 | -117.63 Thousand USD | -674.14% |
| 2008 FY | - USD | -999.29% |
| 2008 Q3 | -176.2 Thousand USD | -49.8% |
| 2008 Q4 | -216.35 Thousand USD | -22.78% |
| 2007 Q2 | -13.42 Thousand USD | -42.22% |
| 2007 Q3 | -9100.00 USD | 32.19% |
| 2007 Q1 | -9436.00 USD | 0.0% |
| 2007 Q4 | -16.2 Thousand USD | -78.08% |
| 2007 FY | - USD | -36.01% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.146% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 53.819% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.731% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 84.237% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.912% |
| Mesoblast Limited | -62.38 Million USD | 95.611% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -78.25% |
| Genus plc | 73.7 Million USD | 103.715% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 58.587% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 22.808% |
| Marizyme, Inc. | -34.28 Million USD | 92.013% |
| ContraFect Corporation | -64.99 Million USD | 95.788% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 68.787% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 39.508% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -95.319% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -3.538% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -17.823% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -428.524% |
| Accustem Sciences Inc. | -3.74 Million USD | 26.917% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.323% |
| EV Biologics, Inc. | -1.26 Million USD | -116.079% |
| Q BioMed Inc. | -617.62 Thousand USD | -343.309% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 176.652% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -332.95% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -19.852% |
| Biomind Labs Inc. | -1.03 Million USD | -164.656% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 127.721% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 61.767% |
| Skye Bioscience, Inc. | -13.54 Million USD | 79.79% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -84.078% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -10852.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 29.511% |
| IMV Inc. | -35.52 Million USD | 92.292% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 82.747% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -9.434% |
| GB Sciences, Inc. | -1.41 Million USD | -92.833% |
| Alpha Cognition Inc. | -9.7 Million USD | 71.789% |
| HST Global, Inc. | -5303.00 USD | -51531.152% |
| CSL Limited | 4.78 Billion USD | 100.057% |
| Halberd Corporation | -74.27 Thousand USD | -3586.102% |
| Enzolytics Inc. | -2.12 Million USD | -29.027% |
| Resverlogix Corp. | -11.74 Million USD | 76.682% |
| Affymax, Inc. | -14.29 Million USD | 80.846% |
| SYBLEU INC | -141.57 Thousand USD | -1834.012% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 10.611% |
| argenx SE | -216.02 Million USD | 98.733% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.052% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 324.979% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -82.667% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 822.725% |
| AVAX Technologies, Inc. | -6.11 Million USD | 55.208% |
| Zenith Capital Corp. | -8.6 Million USD | 68.185% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.899% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15616.664% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -11.917% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1455.467% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.092% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 5.336% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -161.681% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 40819.81% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -56.457% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -42.537% |
| BioStem Technologies, Inc. | -7.55 Million USD | 63.753% |
| ONE Bio Corp. | 13.61 Million USD | 120.113% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1411.972% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -33.106% |
| Agentix Corp. | -1.37 Million USD | -99.598% |
| LadRx Corporation | 412.28 Thousand USD | 764.107% |
| Cell Source, Inc. | -4.27 Million USD | 35.916% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -645.6% |
| Regen BioPharma, Inc. | 1.46 Million USD | 286.772% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -192.225% |
| NovAccess Global Inc. | -1.03 Million USD | -164.593% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 130.925% |
| Itoco Inc. | -1.86 Million USD | -46.496% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -621.248% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -145.341% |
| Kadimastem Ltd | -2.62 Million USD | -4.329% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1044.888% |
| CytoDyn Inc. | -18.02 Million USD | 84.813% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3364.551% |
| Mobile Lads Corp. | -2.24 Million USD | -22.169% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -22289.402% |
| Qrons Inc. | -40.08 Thousand USD | -6731.167% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -463.748% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 619.118% |
| Rebus Holdings, Inc. | -951 Thousand USD | -187.907% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -157.813% |
| International Stem Cell Corporation | 202 Thousand USD | 1455.446% |
| Bioxytran, Inc. | -3.82 Million USD | 28.327% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5101.368% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -11.213% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 92.367% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5984.444% |
| Neutra Corp. | -181.24 Thousand USD | -1410.646% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 86.418% |
| PureTech Health plc | -11.62 Million USD | 76.451% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 86.417% |
| IXICO plc | -707 Thousand USD | -287.27% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 64.372% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.337% |
| CSL Limited | 4.73 Billion USD | 100.058% |
| Cellectis S.A. | -92.63 Million USD | 97.044% |